Expanded Investor Syndicate
Galecto Biotech AB announced May 2, 2012 that the company’s first financing round has been expanded and that two new investors, SEED Capital and Sunstone Capital, will join Novo A/S and Merck Serono Ventures in the company’s investor syndicate. The company will use the proceeds to advance its unique galectin modulators, which have the potential to treat a range of life threatening diseases.
News